Leerink Partnrs Weighs in on Quanterix FY2027 Earnings

Quanterix Corporation (NASDAQ:QTRX - Free Report) - Analysts at Leerink Partnrs issued their FY2027 earnings per share (EPS) estimates for Quanterix in a research note issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda forecasts that the company will earn ($0.65) per share for the year. Leerink Partnrs currently has a "Hold" rating on the stock. The consensus estimate for Quanterix's current full-year earnings is ($0.98) per share.

Quanterix (NASDAQ:QTRX - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The company reported ($0.53) earnings per share for the quarter, beating analysts' consensus estimates of ($0.69) by $0.16. Quanterix had a negative net margin of 36.82% and a negative return on equity of 15.07%. The firm had revenue of $30.33 million for the quarter, compared to analyst estimates of $28.27 million.

QTRX has been the topic of several other reports. Wall Street Zen lowered shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Scotiabank reissued an "outperform" rating on shares of Quanterix in a research note on Tuesday, March 25th. Canaccord Genuity Group lowered their target price on shares of Quanterix from $15.00 to $12.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Finally, Leerink Partners reissued a "market perform" rating and set a $8.00 target price (down from $12.00) on shares of Quanterix in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average price target of $13.50.

Quanterix Price Performance

NASDAQ:QTRX traded down $0.14 during mid-day trading on Friday, hitting $5.37. The company's stock had a trading volume of 482,164 shares, compared to its average volume of 614,417. Quanterix has a 1 year low of $4.05 and a 1 year high of $16.01. The stock has a market cap of $268.23 million, a price-to-earnings ratio of -4.13 and a beta of 1.13. The business's fifty day moving average is $5.73 and its two-hundred day moving average is $6.88.

Insider Activity at Quanterix

In related news, Director William P. Donnelly acquired 93,113 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average price of $5.44 per share, with a total value of $506,534.72. Following the transaction, the director owned 139,094 shares of the company's stock, valued at approximately $756,671.36. This trade represents a 202.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David R. Walt acquired 123,990 shares of the stock in a transaction that occurred on Friday, June 13th. The shares were bought at an average cost of $6.14 per share, with a total value of $761,298.60. Following the transaction, the director directly owned 1,866,933 shares in the company, valued at $11,462,968.62. This trade represents a 7.11% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 463,113 shares of company stock valued at $2,625,444. Corporate insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Quanterix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allspring Global Investments Holdings LLC purchased a new position in Quanterix in the 1st quarter valued at approximately $98,000. JPMorgan Chase & Co. raised its holdings in shares of Quanterix by 23.9% in the 4th quarter. JPMorgan Chase & Co. now owns 270,054 shares of the company's stock valued at $2,871,000 after purchasing an additional 52,097 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Quanterix in the 4th quarter valued at $606,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Quanterix by 18.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,878 shares of the company's stock valued at $361,000 after purchasing an additional 5,385 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Quanterix in the 4th quarter valued at $570,000. Hedge funds and other institutional investors own 86.48% of the company's stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.